Inato Raises $20M in Series A2 Funding
Summary
The company intends to use the new funding for continued product innovation, international growth, and hiring of talent. Inato will advance its diversity product offering to enable sponsors to strategically meet their diversity goals based on new FDA requirements, invest in oncology-specific innovation, further define and scale its data model to continue to improve matching reliability between community sites and sponsor trials. By enabling community research sites to effectively select the right opportunities for them, Inato is helping bring the right trials to patients — regardless of who they are or where they live. To do this, the platform connects global pharmaceutical companies with a broader range of community research sites, while ensuring high performance through collaborative, evidence-based enrollment planning and ongoing support. Launched in late 2020, the platform has amassed over 2,500 community research sites that support more than 70 disease areas in more than 60 countries.